title: Short communication: Paraoxonase 1 (PON1) in French HIV-infected patients under antiretroviral therapy: relationship with the metabolic syndrome and inflammation.
abstract: Our goal was to determine if paraoxonase 1 (PON1) activity relates to the presence of metabolic syndrome (MS) and inflammation in HIV patients treated with highly active antiretroviral therapy (HAART). This was a prospective, multicenter study including 269 patients receiving HAART for at least 1 year and a maximum of 4 years. PON1 and inflammatory markers [C reactive protein (CRP), interleukin-6 (IL-6), serum amyloid A (SAA), and soluble tumor necrosis factor receptors 2 (sTNF-R2)] were compared between patients with or without MS and the association between inflammatory markers and PON1 was assessed by logistic regression analyses. MS was found in 18.2% of the patients. Inflammatory markers, with the exception of sTNF-R2, were significantly higher, while PON1 activity was significantly lower in the presence of metabolic syndrome. PON1 activity was significantly related to apolipoprotein C3, CD4 count, and sTNF-R2. It may be concluded that PON1 appears to be a marker for the metabolic syndrome in HIV-infected subjects. PON1 activity is related to dyslipidemia and the immunological status of the patients but is not fully determined by inflammation.
authors.affiliation: 1 Université de Nantes, EA 2160, Centre de Recherche en Nutrition Humaine (CRNH) et Institut de Cancérologie de l'Ouest René Gauducheau , Nantes, France .
authors.forename: Christine
authors.initials: C
authors.lastname: Bobin-Dubigeon
authors.forename: Charlotte
authors.initials: C
authors.lastname: Biron
authors.forename: Christelle
authors.initials: C
authors.lastname: Volteau
authors.forename: Lionel
authors.initials: L
authors.lastname: Piroth
authors.forename: Antoine
authors.initials: A
authors.lastname: Biron
authors.forename: Philippe
authors.initials: P
authors.lastname: Perré
authors.forename: Catherine
authors.initials: C
authors.lastname: Leport
authors.forename: Thierry
authors.initials: T
authors.lastname: Prazuck
authors.forename: Veronique
authors.initials: V
authors.lastname: Sébille-Rivain
authors.forename: François
authors.initials: F
authors.lastname: Raffi
authors.forename: Jean Marie
authors.initials: JM
authors.lastname: Bard
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D043303:Aryldialkylphosphatase / Q000378:metabolism*; D005602:France; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007249:Inflammation / Q000150:complications*; D024821:Metabolic Syndrome / Q000150:complications*
chemical_list: D019380:Anti-HIV Agents; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human